Dr. Abou-Alfa on the Role of Immunotherapy in HCC

Ghassan K. Abou-Alfa, MD
Published: Friday, May 05, 2017



Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

The role of immunotherapy could be extending beyond systemic disease because there is interest in combining it with local therapy, explains Abou-Alfa.

There are preliminary data focused on a combination of local therapy and an immunotherapy regimen, which demonstrates a potential success, states Abou-Alfa.
 


Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy for patients with hepatocellular carcinoma (HCC).

The role of immunotherapy could be extending beyond systemic disease because there is interest in combining it with local therapy, explains Abou-Alfa.

There are preliminary data focused on a combination of local therapy and an immunotherapy regimen, which demonstrates a potential success, states Abou-Alfa.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x